This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre Hospitalier Universitaire De Toulouse, Centre National De La Recherche Scientifique, Institut Claudius Regaud. Active years: 2021.
Company Filing History:
1 out of 29 
1 out of 5,383 
1 out of 6 
Years Active: 2021
Title: Loïc Ysebaert: Innovator in Tumor-Targeting Antibodies
Introduction
Loïc Ysebaert is a prominent inventor based in Toulouse, France. He has made significant contributions to the field of medical research, particularly in the development of antibodies that target tumor-associated macrophages. His innovative work has the potential to advance cancer treatment and improve patient outcomes.
Latest Patents
Ysebaert holds a patent for "Antibodies targeting tumor associated macrophages and uses thereof." This invention focuses on antibodies that specifically target Tumor Associated Macrophages (TAMs). The research conducted by Ysebaert and his team identified a specific marker on the surface of macrophages associated with tumors, allowing for the detection and targeting of TAMs. They discovered that sideroflexin 3, which is not present in normal macrophages, is expressed by tumor-associated macrophages. The team demonstrated that by using antibodies directed at sideroflexin 3, they could deplete TAMs in PBMC samples obtained from leukemia patients, significantly reducing the number of leukemic B cells.
Career Highlights
Throughout his career, Loïc Ysebaert has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paul Sabatier Toulouse. His research has been pivotal in understanding the role of macrophages in cancer and developing targeted therapies.
Collaborations
Ysebaert has collaborated with notable colleagues, including Mary Poupot and Marie Tosolini. Their combined expertise has contributed to the advancement of research in the field of tumor immunology.
Conclusion
Loïc Ysebaert's innovative work in targeting tumor-associated macrophages represents a significant advancement in cancer research. His contributions have the potential to lead to more effective treatments for patients suffering from leukemia and other cancers.